Multi-Channel Engagement and Pharmacist-Prescriber Collaboration in Tardive Dyskinesia Care

This episode, titled 'Multi-Channel Engagement and Pharmacist-Prescriber Collaboration in Tardive Dyskinesia Care,' featured panelists discussing the following critical questions:

What multi-channel strategies can reinforce provider engagement with vesicular monoamine transporter 2 (VMAT2) inhibitor messaging outside traditional visits?

How can pharmacists and prescribers collaborate to ensure smooth transitions from treatment initiation to maintenance?

Led by the moderator, the expert psychiatry pharmacists discussed multi-channel strategies for reinforcing provider engagement with tardive dyskinesia (TD) education, highlighting the value of interactive applications, patient advocate testimonials shared through television and social media platforms, and early education for pharmacy students to help reduce stigma and build confidence in addressing TD over time. Melissa Cloyd and Jamie Kneebusch emphasized that breaking the stigma surrounding TD requires sustained, repeated messaging across multiple channels, much like cultural shifts seen with other historically stigmatized health conditions. The panelists then explored how pharmacists and prescribers can collaborate to ensure smooth transitions from treatment initiation to maintenance, underscoring the pharmacist's role in supporting appropriate titration, ongoing monitoring, prior authorization navigation, and provider education to build confidence in prescribing VMAT2 inhibitors as part of a unified, patient-centered care team.

Throughout the conversation, the experts provided a comprehensive reflection on the field and the factors that may shape how clinicians approach care moving forward.

In the next episode, 'Closing the Loop: Outcome Metrics and Final Reflections on Tardive Dyskinesia Management,' panelists continue their discussion on tardive dyskinesia and highlight the metrics and feedback mechanisms used to track the success of interventions aimed at improving TD recognition and therapy persistence, along with final takeaways from the panel on TD recognition and management.